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Abstract 
Background: A novel MRI technique, employing dual contrast manganese-enhanced MRI (MEMRI) and delayed 
enhancement MRI (DEMRI), can evaluate the physiologically unstable peri-infarct region. Dual contrast MEMRI–DEMRI 
enables comprehensive evaluation of telmisartan to salvage the peri-infarct injury to elucidate the underlying mecha-
nism of restoring the ischemic cardiomyopathy in the diabetic mouse model.
Methods and results: Dual contrast MEMRI–DEMRI was performed on weeks 1, 2, and 4 following initiation of tel-
misartan treatment in 24 left anterior descendent artery ligated diabetic mice. The MRI images were analyzed for core 
infarct, peri-infarct, left ventricular end-diastolic, end-systolic volumes, and the left ventricular ejection fraction (LVEF). 
Transmission electron microscopy (TEM) and real-time PCR were used for ex vivo analysis of the myocardium. Tel-
misartan vs. control groups demonstrated significantly improved LVEF at weeks 1, 2, and 4, respectively (33 ± 7 %*** 
vs. 19 ± 5 %, 29 ± 3 %*** vs. 22 ± 4 %, and 31 ± 2 %*** vs 18 ± 6 %, ***p < 0.001). The control group demonstrated 
significant differences in the scar volume measured by MEMRI and DEMRI, demonstrating peri-infarct injury. Telmisar-
tan group significantly salvaged the peri-infarct injury. The myocardial effects were validated by TEM, which confirmed 
the presence of the injured but viable cardiomyocyte morphology in the peri-infarct region and by flow cytometry of 
venous blood, which demonstrated significantly increased circulating endothelial progenitor cells (EPCs).
Conclusion: The improved cardiac function in ischemic cardiomyopathy of diabetic mice by telmisartan is attributed 
to the attenuation of the peri-infarct injury by the angiogenic effects of EPCs to salvage the injured cardiomyocytes. 
Dual-contrast MEMRI–DEMRI technique tracked the therapeutic effects of telmisartan on the injured myocardium 
longitudinally.
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Background
Diabetes mellitus currently afflicts 171 million people 
worldwide and its prevalence continues to rise [1, 2]. The 
adverse cardiovascular consequences of diabetes mellitus 
are recognized by the accelerated rate of atherosclerosis, 
predisposing patients to coronary artery disease, myocar-
dial infarction, and death [3, 4].
Angiotensin-converting enzyme inhibitors (ACE) has 
been repeatedly shown to decrease cardiovascular mor-
tality in the diabetic population [5]. Angiotensin-receptor 
blockers (ARB) were developed for patients intolerant of 
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ACE inhibitors and have similarly shown to reduce major 
cardiovascular disease outcomes [6]. Telmisartan, in par-
ticular, has been shown to be equivalent to ACE inhibi-
tors in providing cardiovascular protection in high-risk 
heart failure patients, particularly the diabetic population 
[7, 8]. It has been postulated that telmisartan may atten-
uate the myocardial injury in DM patients sustaining 
an MI. The anti-apoptotic, anti-fibrotic and angiogenic 
effects of telmisartan with the modulatory role on per-
oxisome proliferator-activated receptor gamma (PPARγ) 
may contribute to the microvasculature of the peri-
infarct region to salvage the injured myocardium, reduce 
the remodeling of the myocardium and improve cardiac 
function [9].
The distinction between reversible and irreversible 
myocardial injury within the region at risk is impera-
tive since the selection of an appropriate therapy can 
alter the overall mortality and morbidity significantly. 
However the distinction between the infarcted myocar-
dium versus the injured but viable myocardium located 
in the peri-infarct region is often difficult to make [10]. 
The current gold standard is DEMRI, which employs a 
gadolinium (Gd3+)-based contrast agent using cardiac 
MRI. However, DEMRI does not provide direct cell via-
bility information due to its non-specific distribution into 
the extracellular space and may overestimate the infarct 
region [11]. Thus dual-contrast MRI has been used to 
provide complementary information [12] and for the 
purpose of directly evaluating cell viability, DEMRI can 
be complemented by MEMRI [13, 14]. MEMRI employs 
Mn2+, an essential heavy metal ion that enters cells via 
voltage-gated calcium channels [15]. Only the viable 
cells are able to accumulate Mn2+ within the intracellu-
lar space, shortening the T1 relaxivity and increasing the 
MRI signal. MEMRI combines high spatial and temporal 
resolution of MRI with a viability-specific intracellular 
signal to identify viable cardiomyocytes [16, 17].
In this study, we performed a dual-contrast DEMRI–
MEMRI to evaluate the peri-infarct region in a diabetic 
murine myocardial injury model. This complementary 
technique assessed the therapeutic effect of telmisartan 
on the peri-infarct region and correlated the reduced 
peri-infarct region with the resultant restoration of car-
diac function [11].
Methods
Diabetic murine myocardial injury model
All animal studies were approved by the Stanford Uni-
versity Administrative Panel on Laboratory Animal Care. 
The C57BL/KLS-leprdb/leprdb (db/db, Jackson Laborato-
ries, Bar Harbor, ME, USA), a transgenic mouse strain 
with an autosomal recessive mutation in the leptin 
receptor, is a well-established animal model of type 2 
diabetes mellitus [18]. Myocardial injury was induced 
in a total of 24 adult db/db mice. This provided a model 
of myocardial injury with an LVEF of 15–20  % in con-
trol groups as previously demonstrated [19]. Mice were 
anesthetized with inhalational isoflurane 1.25–2.0  % 
and subcutaneous buprenorphine 0.1 mg/kg. They were 
intubated to achieve positive pressure ventilation with 
oxygen/isoflurane mixture. Thoracotomy was performed 
and the left anterior descending coronary artery (LAD) 
was ligated until blanching of the distal left ventricle was 
seen. The chest was then closed in layers and the animal 
was placed in the small animal intensive care unit. The 
animals were randomly assigned to either the telmisar-
tan-treated or control group. Telmisartan (10  mg/kg/
day; Boehringer-Ingelheim Co., Ltd.) was administered 
per os in the drinking water 1 week after LAD ligation for 
12 mice (telmisartan group) and tap water was available 
ad libitum for another 12 mice (control group). Telmisar-
tan was dissolved in the drinking water and made fresh 
every 5  days. Five milliliters of telmisartan water was 
available per mouse daily. There were 2–3 mice from the 
same treatment group in each cage. During the treatment 
period, the telmisartan-treated animals were checked 
three times daily to make sure there was enough drinking 
water available for them. Telmisartan water was replen-
ished each morning. When the telmisartan water ran 
out during the day, regular tap water was added to keep 
them hydrated. Imaging was performed an additional 
week after LAD ligation (i.e., 1  week after treatment). 
The corresponding weeks 1, 2 and 4 referred to in the 
manuscript refer to weeks after treatment. Due to severe 
myocardial injury in this already morbid mouse strain, 
we observed an increased mortality rate of approximately 
75  % in both groups at the end of the study. There was 
no significant difference between the telmisartan and 
control groups in terms of mortality. At a minimum, the 
mice were monitored twice daily (in the early morning 
and late afternoon, including weekends and holidays) 
and any animals displaying clinically abnormal behavior 
were removed from the group and instead housed indi-
vidually with ready access to food and water. Treatment 
for the telmisartan mice was continued throughout the 
study. Supportive care was provided in the form of water-
soaked pellets placed on the cage floor, administration of 
subcutaneous fluids, and provision of a high calorie oral 
supplement (e.g., Diet Gel, Nutri-Gel, Nutrical). Regular 
mouse diet and dark/light cycle were provided to the ani-
mals. We did perform 3 additional MRI studies for week 
2 for the control group to further increase the number 
and these numbers also contributed to pressure–volume 
analyses and in vitro tests at the conclusion of the study.
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In vivo MEMRI and DEMRI
Anesthesia was induced and maintained with 1.25–2.0 % 
isoflurane. ECG leads were inserted subcutaneously 
to assess the heart rate while the body temperature 
was maintained at 37  °C and the respiratory rate was 
monitored. Using a 3T GE Signa Excite scanner with a 
dedicated mouse surface receive-only coil (Rapid MR 
International, Germany), multiple cardiac functional 
parameters were obtained on weeks 1, 2, and 4 after ini-
tiation of telmisartan treatment. The following sequences 
were performed for MRI acquisitions: (1) MEMRI was 
performed using fast gradient echo inversion recovery 
(GRE-IR) sequence with FOV 4 cm, slice thickness 1 mm, 
matrix 256 ×  256, TE 3.4 ms, FA 45°, 2R-R acquisition, 
TI 300-500 ms, and NEX2 with an intraperitoneal injec-
tion of 0.7 cc/kg of Eagle Vision Pharmaceutical manga-
nese-based contrast solution (EVP1001-1, Eagle Vision 
Pharmaceutical Corp) prior to MEMRI acquisition; (2) 
DEMRI was performed 24 h later with an intraperitoneal 
injection of 0.2  mmol/kg gadopentetate dimeglumine 
(Magnevist, Berlex Laboratories) using a similar GRE-
IR sequence but with a TI of 200-300 ms; and (3) cardiac 
MRI of LV volumes and function were performed on the 
day of MEMRI using fast spoiled gradient echo with FOV 
5 cm, slice thickness 1 mm, matrix 256 × 256, TE 5 ms, 
and FA 30. Consecutive short axis slices were obtained 
for quantitative analysis for LV volumes and function 
and DEMRI and MEMRI volumes. For LV volumes and 
function assessment, 20 cardiac phases were obtained 
for each short axis slice and typically 5–7 short axis slices 
were obtained for each mouse. Injection of contrast was 
performed 30 and 10 min prior to image acquisition for 
MEMRI and DEMRI respectively. The optimal timing of 
contrast injection prior to image acquisition was previ-
ously determined by observation of peak signal to noise 
ratio for both MEMRI and DEMRI.
MRI image analysis
For each short-axis slice, planimetry measurements of the 
LV myocardium were conducted off-line by manual trac-
ing of the epicardial and endocardial borders at end-sys-
tole and end-diastole with OsiriX (Pixmeo Inc., Geneva, 
Switzerland). Manual tracings were not statistically dif-
ferent from semi-automatic full width half maximum 
tracings as demonstrated in a previous study [11]. The 
papillary muscles were considered part of the LV cavity. 
Left ventricular mass, LV end-diastolic volume (LVEDV), 
and LV end-systolic volume (LVESV) were measured 
to calculate the LVEF. For infarct analysis, the MEMRI 
defect area and the DEMRI enhanced area were desig-
nated as scar tissue. These areas were traced in short-axis 
slices, using cine images for comparison, and integrated 
to determine scar volumes by MEMRI and DEMRI in 
matched mice hearts (n = 24). The % MEMRI scar vol-
ume =  (MEMRI defect volume/total LV volume) × 100 
and % DEMRI scar volume = (DEMRI scar volume/total 
LV volume) × 100. The difference between MEMRI and 
DEMRI defect volumes defined the peri-infarct volume.
Pressure–volume loop analysis
At the end of the study, ventricular performance was 
assessed by pressure–volume (PV) loop analysis with 
a 1.4F conductance catheter (Millar Instruments, Inc., 
Houston, TX) before the animals were sacrificed in 8 
mice (telmisartan group, n  =  4; control group, n  =  4) 
[19]. The right carotid artery was cannulated with the 
Millar catheter that was advanced through the aortic 
valve into the left ventricle. The PV relations were meas-
ured at baseline and during inferior vena caval occlusion. 
When coupled with pressure, the generation of ventricu-
lar PV relationships allowed precise hemodynamic char-
acterization of ventricular systolic and diastolic function 
and loading conditions. These data were analyzed with 
PVAN 3.4 Software and Chart/Scope software (ADIn-
struments, Inc., Colorado Springs, CO).
Flow cytometry
Venous blood was obtained from the inferior vena cava 
at the end of the study for 8 mice (telmisartan group, 
n = 4; control group, n = 4). The whole blood was then 
centrifuged 5 min at 3000 rpm and the supernatant sub-
sequently removed. The pellets were resuspended by 
equal volume of ACK lysis buffer (Lonza, Allendale, NJ) 
to remove red blood cells and centrifuged again. The pel-
lets were washed and resuspended in 100  μL PBS with 
5 % fetal bovine serum and stained with purified primary 
anti-human CD34 antibody (BD Pharmingen, San Diego, 
CA) and PE anti-mouse IgG secondary antibody. The cells 
were then evaluated by multi-color flow cytometry using 
FACScalibur (BD Biosciences, San Jose, CA) with subse-
quent analysis of data in FlowJo (Tree Star, Ashland, OR).
Real‑time PCR
Total mRNA was isolated from telmisartan-treated and 
control myocardial tissue at the end of the study (tel-
misartan group, n  =  2; control group, n  =  2). Total 
mRNA was then reverse-transcribed into cDNA. Real-
time quantitative PCR was run on a 96 well real-time 
PCR thermocycler using Power SYBR Green master mix 
(AB, USA), according to the manufacturer’s recommen-
dations. Primers for collagen I, collagen III, connective 
tissue growth factor (CTGF), TGFβ, fibronectin, and Akt 
were synthesized by Invitrogen (in the order of forward 
and reverse:
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collagen I: CCTGGAATGAAGGGACAC and GAGC 
TCCGTTTTCACCAG;
collagen III: AAAAGGGTCCTCCCGGAGA and TTC 
CATCATTGCCTGGTC;
CTGF: CAACCGCAAGATCGGAGT and GTCGGT 
AGGCAGCTAGGG;
TGFβ: AAGCGCCCGGGTTGTGTTGG and CTGT 
ACATTGACTTTAGG;
fibronectin: TCTGTGCCACTTCCCCTT and ATAC 
ATGACCCCTTCATT; and
Akt: TTGAGCGCACCTTCCATG, TTCATGGTCAC 
ACGGTGC). The GAPDH housekeeping gene (CCT 
CAAGGGCATCCTGGGCT, GCTGGTGGTCCAGG 
GGTCTT) was used as reference for the relative quan-
tification of the genes of interest. Despite the small 
sample size, we previously were able to demonstrate 
statistical significance with similar numbers [19].
Immunohistology and transmission electron microscopy
At the end of the study, explanted hearts were fixed with 
4 % formalin and paraffin embedded and standard hema-
toxylin and eosin staining was performed on short axis 
sections.
For TEM, remote, peri-infarct and infarct regions were 
identified using Evan’s blue dye (EBD). EBD enters car-
diac myocytes through injured sarcolemma and thus 
clearly identifies the infarct region. 90  μL of EBD was 
injected intraperitoneally, at a concentration of 10  mg 
per mL of PBS, 24  h prior to explantation. The follow-
ing day, the myocardial tissue from a telmisartan-treated 
diabetic mouse 5 weeks post LAD ligation was obtained 
from the remote, peri-infarct and infarct regions and 
then cut into pieces (3–4 pieces per region) and fixed 
with 2 % glutaraldehyde and 4 % paraformaldehyde. The 
remote, peri-infarct and infarct zones were also co-local-
ized with MEMRI and DEMRI images with the overlap of 
DEMRI and MEMRI enhancement identifying the peri-
infarct region. Further fixation was performed with 1 % 
osmiumtetroxyde. After dehydration and embedding, 
sections were analyzed by a JEOL 1230 tissue electron 
microscope (JEOL Ltd., Tokyo, Japan) at 80 keV. Ultras-
tructural analysis of the cardiomyocytes was performed 
by blinded observers; assessing ‘healthy’ and ‘unhealthy’ 
features of cell integrity and sarcomeric organization 
[11]. For ‘healthy’ features, each cardiomyocyte was 
graded on whether it exhibited (Table: black): ‘5’—high 
abundance; ‘4’— moderate abundance; ‘3’—low abun-
dance; ‘2’—rare; or ‘1’—complete absence of that feature. 
Conversely, for an ‘unhealthy’ TEM feature (Table: red): 
‘5’ indicated that the nucleus displayed complete absence; 
‘4’—rare; ‘3’—low abundance; ‘2’—moderate abundance; 
and ‘1’—high abundance of the ‘unhealthy’ feature. Indi-
vidual scores from 10 to 15 myocytes per zone were 
averaged to generate an overall zone score for that feature 
from 1 to 5. The 17 scores were averaged to generate a 
composite score for each zone that reflected the overall 
structural integrity of the cells within each zone, with ‘5’ 
being the best and ‘1’ being the worst score. Agreement 
on TEM scoring between two independent observers was 
high (Kappa =  0.74). Composite scores were compared 
between remote zone, border zone, and core infarct zone 
TEM.
Statistical analysis
Results are mean  ±  standard deviation. Comparison 
between groups was performed with the Wilcoxon rank-
sum test. Significant differences (p  <  0.05) among the 
TEM of the three regions (remote, intra-infarct and peri-
infarct regions) were tested using one-way analysis of 
variance (ANOVA).
Results
Left ventricular systolic function, volume, and morphology
At weeks 1, 2, and 4, LVEF was severely reduced (19 ± 5, 
22 ± 4 and 18 ± 6 %, respectively) in the control group. 
However, the telmisartan group demonstrated signifi-
cant and sustained increase in LVEF at each time point 
(33 ± 7 %***, 29 ± 3 %*** and 31 ± 2 %***, ***p < 0. 001) 
as demonstrated in Fig. 1. The LVESV and LVEDV (μL) 
at weeks 1, 2, and 4 in the telmisartan vs. control groups 
(LVESV: 43 ± 31 vs. 38 ± 14; 24 ± 12 vs. 33 ± 12; and 
43 ±  10 vs. 44 ±  10 and LVEDV: 63 ±  39 vs. 46 ±  15; 
33 ± 16 vs. 43 ± 17, and 62 ± 14 vs. 54 ± 12) demon-
strated no significant change. When comparing serially 
from week 1 to 4 within each group, LVESV and LVEDV 
in the telmisartan group demonstrated no change while 
the control group demonstrated a trend to increased LV 
volumes. The increase in LVEF was not associated with 
Fig. 1 Functional measurement of telmisartan versus control groups. 
Significantly improved LVEF at weeks 1, 2, and 4 (***p < 0.001) in 
the telmisartan-treated (red bar) diabetic mice compared to control 
diabetic mice (white bar)
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decreased afterload. Thus the increased LV output was 
not likely related to telmisartan’s potential to reduce 
blood pressure and thereby, afterload. There was no sig-
nificant difference in the systemic end-diastolic pressure 
or tau, the isovolumic relaxation constant, as shown in 
Fig. 2. 
MEMRI and DEMRI scar volume
MEMRI showed reproducible and homogeneous myo-
cardial Mn2+ uptake in remote (normal) areas of the 
myocardium. Within the anteroseptal, anterior, and 
anterolateral regions, MEMRI signal defect was con-
sistently observed as demonstrated in Fig. 3a. This cor-
responded to the enhanced infarct zone of DEMRI 
images as shown in Fig.  3b. The infarct volume (% LV 
myocardium) at weeks 1, 2, and 4 were measured by 
MEMRI and DEMRI, respectively, for telmisartan and 
control groups (telmisartan: 32.0 ± 14.8 vs. 27.1 ± 11.7; 
28.5 ± 2.5 vs. 43.0 ± 3.7; and 30.7 ± 2.6 vs. 44.5 ± 6.1; 
and control: 19.5  ±  15.2 vs. 37.6  ±  13.4; 20.1  ±  8.2 
vs. 31.6  ±  7.3***; and 17.0  ±  3.0 vs. 38.3  ±  7.5***, 
***p  <  0.001). The quantitative measurement of the 
MEMRI defect volume revealed the scar volume was not 
significantly different from DEMRI measurements in 
the telmisartan group (Fig. 4a) while significantly lower 
than the corresponding DEMRI measurements at weeks 
2 and 4 in the control group (Fig.  4b). This significant 
difference between MEMRI and DEMRI scar volumes 
represented the peri-infarct region (Fig.  3c). The sig-
nificant difference between the smaller MEMRI defect 
and the larger DEMRI scar volume delineated the pres-
ence of the injured but viable (MEMRI) cardiomyocytes 
within the scar (DEMRI) region. This finding enabled 
volumetric measurement of the peri-infarct region and 
assessment of the potential mechanism of telmisartan in 
salvaging the injured myocardium. The control group at 
weeks 2 and 4 demonstrated the persistence of myocar-
dial injury, resulting in the persistence of the peri-infarct 
region. On the other hand, telmisartan treatment attenu-
ated this injury, minimizing the area at risk in the peri-
infarct region at week 4 as illustrated in Fig. 4c.
Myocardial fibrosis and apoptosis
Expressions of molecular markers for fibrosis (collagen I, 
collagen III, CTGF, TGFβ, and fibronectin) and apopto-
sis (Akt) were measured in telmisartan and control mice 
heart tissue using real-time PCR. Following 4-week dura-
tion of telmisartan treatment, there was a trend towards 
increased expression of fibrotic genes, including collagen 
I, collagen III, CTGF and fibronectin (Fig.  5). Up-regu-
lation of these genes re-establishes extracellular matrix 
homeostasis to attenuate left ventricular remodeling [20]. 
This increased trend may modulate the fibrosis of the 
infarcted region and salvage the injured but viable car-
diomyocytes to stabilize the peri-infarct region by weeks 
2 and 4.
Hematoxylin and eosin stain and TEM of myocardial injury
The hematoxylin and eosin stain and TEM validated the 
MEMRI–DEMRI assessment of the remote, peri-infarct, 
and infarcted myocardium (Fig.  6a–d). The hematoxylin 
and eosin stain demonstrated the homogeneous myo-
cardial tissue in the remote (normal) zone. The infarcted 
region exhibited diffuse fibrotic and calcified appearance 
consistent with the infarct core. However, the peri-infarct 
border zone showed heterogeneous characteristics of the 
injured but viable cardiomyocytes. The ultrastructural 
characteristics of the cardiomyocytes within the remote, 
peri-infarct, and infarcted regions in a telmisartan-treated 
diabetic mouse was further characterized by TEM of nine 
myocardial samples from the three regions, using previ-
ously established quantitative characterization of normal 
nuclear, chromatin, mitochondrial, and sarcomeric struc-
ture and organization. The subcellular characteristics of 
Fig. 2 Invasive hemodynamic analysis. No significant difference is 
seen in the telmisartan-treated (red bar) diabetic mice compared 
to control diabetic mice (white bar) for both systemic end-diastolic 
pressure and the isovolumic relaxation constant, Tau, calculated by 
the Glantz method
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the remote, peri-infarct, and infarcted zones were quan-
titatively analyzed (Table 1). As expected, the subcellular 
organelles were destroyed in the infarcted region (overall 
TEM score: 1.2 ± 0.2, n = 17). However, the peri-infarct 
region exhibited injured but viable subcellular structure, 
demonstrating significant difference in the score from 
both the remote and infarct region (3.1 ± 0.4*, p < 0.05). 
The remote region displayed normal ultrastructure of via-
ble cells (4.7 ± 0.3). The TEM data indicated the presence 
of injured but viable cardiomyocytes with intact subcellu-
lar organelles, which validated the MEMRI–DEMRI sig-
nal consistent with the presence of the injured but viable 
cardiomyocytes in the peri-infarct region.
Flow cytometry for circulating CD34 + cells
Flow cytometry performed on whole blood demon-
strated a significant increase in circulating CD34 + cells 
in the telmisartan-treated vs. control mice (53.5  %* vs. 
5.0 %, *p < 0.05), which constitute the EPCs, as demon-
strated in Fig. 7 [21–23].
Discussion
The current study confirmed the benefit of telmisartan 
in improving the cardiac function in the diabetic murine 
myocardial injury model. Dual-contrast MRI tracked the 
therapeutic effects of telmisartan on the injured but via-
ble myocardium in the peri-infarct region. Telmisartan 
Fig. 3 Corresponding short-axis MEMRI and DEMRI. a MEMRI defect representing myocardial scar (red tracing), b DEMRI enhancement depicting 
myocardial scar (red tracing), and c overlapping area between MEMRI and DEMRI in the border zone illustrates the viable peri-infarct region (yellow 
tracing)
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Fig. 4 MEMRI and DEMRI enable peri-infarct volume measurements. DEMRI % scar volume does not differ significantly from the MEMRI % scar 
volume in the a telmisartan group (red and dark red bars) while b the DEMRI and MEMRI % scar volume difference is significant in the control (white 
and black bars) group for weeks 2 and 4. c The telmisartan group demonstrates decreased % peri-infarct volume compared to the control group at 
week 4
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treatment demonstrated significant attenuation of the 
peri-infarct region with resultant improved LV func-
tion. Afterload reduction did not contribute to improved 
LV function, signifying the importance of the role of the 
injured but viable cardiomyocytes in the peri-infarct 
region to restore cardiac function. These data, validated 
by TEM, supported the study’s finding that the underly-
ing mechanism of telmisartan in restoring the myocar-
dium is predominantly due to the significant salvage of 
the peri-infarct region. In addition, high morbidity and 
mortality of advanced heart failure are associated with 
ventricular arrhythmia and LV remodeling in the peri-
infarct region [24]. The peri-infarct region has been rec-
ognized as an important substrate to trigger ventricular 
arrhythmias and revascularization of the ischemic peri-
infarct region have been shown to lower the incidence of 
ventricular arrhythmias and LV remodeling [25].
The renin-angiotensin system plays a critical role in 
the pathophysiology of cardiovascular disease [26]. Tel-
misartan shows high affinity for the AT1 receptor with 
the longest half-life (24  h) of any ARB [27]. Activation 
of AT1 by angiotensin II leads to molecular and cellular 
events involved in endothelial damage and progression 
of atherosclerosis, which is attenuated by telmisartan. 
Endothelial regeneration is not only accomplished by 
resident endothelial cells but also by EPCs [28]. Poor gly-
cemic control in the diabetic population correlates with 
significantly decreased circulating EPCs [29]. Impaired 
function and quantity of circulating EPCs are associated 
with poor cardiovascular outcomes in patients with coro-
nary artery disease [28, 30]. Endtmann et  al. [28] dem-
onstrated that angiotensin II consistently decreased the 
proliferation of EPCs in  vitro and in  vivo through the 
activation of AT1. As suggested by the flow cytometry 
data, telmisartan increased the number of circulating 
EPCs and may have led to an improved physiologic func-
tion of the endothelium and neovascularization in the 
peri-infarct region. Although afterload reduction effects 
of ARBs can modulate the vascular phenotype to pre-
serve normal flow-mediated vasodilation, the study did 
not demonstrate any significant afterload reduction with 
telmisartan.
In addition to blocking the renin-angiotensin system, 
telmisartan acts as a selective modulator of PPARγ, a 
central regulator of insulin and glucose metabolism and 
a well-known target of insulin-sensitizing drugs used 
to treat type 2 diabetes mellitus [9]. Toyama et  al. [30] 
obtained the first evidence that partial PPARγ activity 
of telmisartan contributed to greater vascular protective 
effects of telmisartan than losartan in obese and diabetic 
mice. The underlying mechanism involved the normali-
zation of Akt/eNOS cascade and anti-inflammatory 
effect due to the suppression of NFκB and TNFα. The 
dual effects of telmisartan in selective antagonism of the 
AT1 receptor and modulation of PPARγ may have ame-
liorated the diabetic vascular complications and salvaged 
the injured myocardium.
Finally, up-regulation of the genes specific to the secre-
tion of collagens and CTGF can act to re-establish extra-
cellular matrix homeostasis and ultimately, inhibit cardiac 
fibrosis to attenuate left ventricular chamber dilation post 
myocardial infarction [20]. CTGF, in particular, is a mul-
tifunctional growth and differentiation factor and it can 
promote chemotaxis, migration, adhesion, proliferation, 
differentiation and/or extracellular matrix formation [31]. 
Fig. 5 Myocardial fibrosis and apoptosis. Real-time PCR quantitative 
analysis of fibrotic (collagen I, collagen III, connective tissue growth 
factor (CTGF), TGFβ, and fibronectin) and apoptotic (thymoma viral 
proto-oncogene 1: Akt) genes in the injured myocardium of telmisar-
tan and control groups. There was a trend towards increased expres-
sion of fibrotic genes, collagen I, collagen III, CTGF and fibronectin 
in the telmisartan group compared to the control group. Red bar: 
telmisartan group, white bar: control group
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Its specific effects depend on the type of cell with which it 
interacts. CTGF has been shown to bind to IGF and VEGF 
to modulate their actions and promote angiogenesis [32]. 
This increased trend of collagen I, collagen III, CTGF and 
fibronectin may explain the underlying mechanism of tel-
misartan in modulating the fibrosis of the infarcted region 
while salvaging the injured but viable cardiomyocytes to 
stabilize the peri-infarct region by weeks 2 and 4.
In this study, the dual contrast MEMRI–DEMRI strat-
egy defined the peri-infarct region to be the border zone 
of the scar where there is significant viable myocardium 
by MEMRI. This novel MRI technique was employed 
to elucidate the potential underlying mechanism of tel-
misartan in restoring the myocardial dysfunction after 
myocardial injury. The ultrastructural analysis of the tel-
misartan group by TEM demonstrated the significantly 
Fig. 6 Hematoxylin and eosin stain and TEM of myocardial injury. a Hematoxylin and eosin stained heart with ROI of remote zone (black line), peri-
infarct region (blue line), and infarct region (green line). b–d TEM images of remote, border, and infarct regions. The three regions exhibited healthy, 
injured but viable, and non-viable cells, respectively. M mitochondria, N nucleus, S sarcomeric structure
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increased presence of viable but injured cardiomyocytes. 
The dual MEMRI–DEMRI contrast technique demon-
strated significant attenuation of the peri-infarct region 
by telmisartan when compared to the control group. This 
significant reduction may underlie the improved myocar-
dial function of telmisartan treatment.
In conclusion, telmisartan demonstrated significant 
functional restoration of the injured diabetic murine 
myocardium by reducing the peri-infarct region, which 
was possibly mediated by increased neovascularization. 
The dual-contrast MEMRI–DEMRI technique enabled 
identification and systematic evaluation of at-risk but via-
ble peri-infarct myocardium.
Limitations
The major limitation of the present study is the higher 
mortality rate of our diabetic mouse model with myo-
cardial injury. With repeated anesthesia necessary for 
serial studies and increased morbidity with this diabetic 
mouse model that was not receiving any diabetic thera-
pies, this resulted in fewer mice that survived at the 
end of the study. Though we still identified significant 
trends, we believe data from more surviving mice would 
have resulted in identifying further meaningful trends. 
Another limitation was that DEMRI and MEMRI were 
performed on consecutive days due to adequate clear-
ance of contrast necessary in between scans. In a prior 
Table 1 Quantitative summary of the different cellular structures in the remote, border and infarct zone in a 4-week tel-
misartan-treated diabetic mouse (* p < 0.05)
*p < 0.05
Cardiomyocyte ultrastructure score by tissue electron microscopy
Cell structure Characteristic feature Remote Border Infract
Mean ± SD Mean ± SD Mean ± SD
Nuclei Notched/furrowed membrane 4.5 ± 0.7 3.9 ± 1.0 1.1 ± 0.4
Homogenous chromatin granules 4.8 ± 0.4 4.3 ± 0.8 1.3 ± 0.5
Chromatin accumulated along nuclear membrane 5.0 ± 0.0 4.2 ± 0.8 1.9 ± 0.6
Chromatin clots within nucleus 4.8 ± 0.4 4.3 ± 0.8 1.3 ± 0.5
Dense chromatin 4.9 ± 0.3 4.3 ± 0.9 1.3 ± 0.5
Dark chromatin finely structured 4.9 ± 0.3 4.5 ± 0.7 1.2 ± 0.4
Mitochondria Dense peri-nuclear accumulation 4.6 ± 0.5 3.8 ± 1.4 1.2 ± 0.4
Fine filaments/glycogen granules between nucleus & mitochondria 4.8 ± 0.4 4.1 ± 1.0 1.3 ± 0.5
Destroyed cristea 4.8 ± 0.4 3.7 ± 1.0 1.1 ± 0.4
Few mitochondria near nucleus 4.8 ± 0.4 3.9 ± 1.5 1.1 ± 0.3
Mitochondria isolated in niche 4.7 ± 0.6 4.1 ± 1.4 1.1 ± 0.4
Myofibrils Myofibrils aligned in one row 4.8 ± 0.5 3.9 ± 0.8 1.0 ± 0.2
T-tubules contain basal lamina 4.9 ± 0.4 4.7 ± 0.6 1.1 ± 0.3
Myofibrils are contracted 4.8 ± 0.4 4.2 ± 0.9 1.0 ± 0.3
Z-line disruption 4.9 ± 0.3 4.1 ± 0.7 1.0 ± 0.2
Lipid droplets between ruptured myofibrils 4.3 ± 0.5 3.6 ± 1.1 1.2 ± 0.4
Collagen 4.0 ± 0.9 3.1 ± 0.9 1.0 ± 0.2
Overall TEM scores 4.7 ± 0.3 3.1 × 0.4* 1.2 × 0.2
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study, no significant difference in infarct size has been 
shown to occur with repeated imaging within 24–48  h 
[33]. However, ideally, both DEMRI and MEMRI would 
be performed in the same scan to limit the potential for 
differences to occur due to timing.
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